Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2

Toni Luise Meister, Yannick Brüggemann, Daniel Todt, Carina Conzelmann, Janis A Müller, Rüdiger Groß, Jan Münch, Adalbert Krawczyk, Jörg Steinmann, Jochen Steinmann, Stephanie Pfaender, Eike Steinmann, Toni Luise Meister, Yannick Brüggemann, Daniel Todt, Carina Conzelmann, Janis A Müller, Rüdiger Groß, Jan Münch, Adalbert Krawczyk, Jörg Steinmann, Jochen Steinmann, Stephanie Pfaender, Eike Steinmann

Abstract

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic creates a significant threat to global health. Recent studies suggested the significance of throat and salivary glands as major sites of virus replication and transmission during early coronavirus disease 2019, thus advocating application of oral antiseptics. However, the antiviral efficacy of oral rinsing solutions against SARS-CoV-2 has not been examined. Here, we evaluated the virucidal activity of different available oral rinses against SARS-CoV-2 under conditions mimicking nasopharyngeal secretions. Several formulations with significant SARS-CoV-2 inactivating properties in vitro support the idea that oral rinsing might reduce the viral load of saliva and could thus lower the transmission of SARS-CoV-2.

Keywords: SARS-CoV-2; inactivation; oral rinses; suspension test; transmission.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Virucidal activity of oral rinses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 strains 1 (dot; UKEssen), 2 (square; BetaCoV/Germany/Ulm/01/2020), and 3 (triangle; BetaCoV/Germany/Ulm/02/2020) were incubated with medium (control) or various oral rinses for 30 seconds. Both conditions were supplemented with an interfering substance mimicking respiratory secretions. Viral titers were determined upon titration on Vero E6 cells. The cytotoxic effect was monitored using noninfected cells incubated with the different products, defined as the lower limit of quantification (LLOQ). The 50% tissue culture infectious dose (TCID50/mL) was calculated according to Spearman–Kärber. Data indicate averages and standard deviation of 3 independent experiments.

References

    1. Anfinrud P, Stadnytskyi V, Bax CE, Bax A. Visualizing speech-generated oral fluid droplets with laser light scattering. N Engl J Med 2020; 382:2061–3.
    1. Wölfel R, Corman VM, Guggemos W, et al. . Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581:465–9.
    1. Meselson M. Droplets and aerosols in the transmission of SARS-CoV-2. N Engl J Med 2020; 382:2063.
    1. Kratzel A, Todt D, V’kovski P, et al. . Inactivation of severe acute respiratory syndrome coronavirus 2 by WHO-recommended hand rub formulations and alcohols. Emerging Infect Dis 2020; 26:1592–5.
    1. O’Donnell VB, Thomas D, Stanton R, et al. . Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function 2020; 1:zqaa002.
    1. Eggers M, Terletskaia-Ladwig E, Enders M. How effective is washing hands against influenza viruses? [in German]. Hyg Med 2009; 34:492–8.
    1. Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther 2018; 7:249–59.
    1. Dennison DK, Meredith GM, Shillitoe EJ, Caffesse RG. The antiviral spectrum of Listerine antiseptic. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79:442–8.
    1. Meiller TF, Silva A, Ferreira SM, Jabra-Rizk MA, Kelley JI, DePaola LG. Efficacy of Listerine antiseptic in reducing viral contamination of saliva. J Clin Periodontol 2005; 32:341–6.
    1. Yamanaka A, Hirai K, Kato T, et al. . Efficacy of Listerine antiseptic against MRSA, Candida albicans and HIV. Bull Tokyo Dent Coll 1994; 35:23–6.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren